Roche's breast cancer entrant Itovebi bolsters clinical profile with overall survival win

Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in combination with two established medicines, new survival data from the drug’s pivotal phase 3 trial show.